Advertisement
Advertisement
LEGN
Legend Biotech Corporation - ADR
20.94
USDSponsored
-0.88
-4.03%
Aug 24, 15:59 UTC -4
Closed
After-Market
21.03
+0.09
+0.43%
LEGN Earnings Reports
Positive Surprise Ratio
LEGN beat 10 of 23 last estimates.
43%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$375.84M
/$0.05
Implied change from Q2 26 (Revenue/ EPS)
-3.01%
/-44.44%
Implied change from Q3 25 (Revenue/ EPS)
+38.01%
/-122.73%
Legend Biotech Corporation - ADR earnings per share and revenue
On Aug 11, 2026, LEGN reported earnings of 0.09 USD per share (EPS) for Q2 26, beating the estimate of 0.07 USD, resulting in a 17.80% surprise. Revenue reached 387.50 million, compared to an expected 362.89 million, with a 6.78% difference. The market reacted with a +5.66% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of 0.05 USD, with revenue projected to reach 375.84 million USD, implying an decrease of -44.44% EPS, and decrease of -3.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.11
Actual
$0.35
Surprise
+198.38%
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
FAQ
What were Legend Biotech Corporation - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Legend Biotech Corporation - ADR reported EPS of $0.09, beating estimates by 17.8%, and revenue of $387.50M, 6.78% above expectations.
How did the market react to Legend Biotech Corporation - ADR's Q2 2026 earnings?
The stock price moved up 5.66%, changed from $20.66 before the earnings release to $21.83 the day after.
When is Legend Biotech Corporation - ADR expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Legend Biotech Corporation - ADR's next earnings report?
Based on 7
analysts, Legend Biotech Corporation - ADR is expected to report EPS of $0.05 and revenue of $375.84M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement